Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation

Trial Profile

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Prediabetic-state; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SCALE; SCALE-Obesity and Pre-diabetes
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Apr 2017 According to a Novo Nordisk media release, the US Food and Drug Administration (FDA) approved an updated product label for Saxenda (liraglutide) injection 3 mg. The label update is based on long term safety and efficacy data from this trial.
    • 27 Feb 2017 Results (n=2254) of 3 years of treatment with liraglutide in adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, published in the Internet Document
    • 01 Nov 2016 Results of population pharmacokinetic analysis in obese patients of this and other two trials published in the Clinical Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top